A citation-based method for searching scientific literature

Diana P Saraiva, M Guadalupe Cabral, António Jacinto, Sofia Braga. ESMO Open 2017
Times Cited: 31







List of co-cited articles
104 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
32

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
19

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
12

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Brian D Lehmann, Bojana Jovanović, Xi Chen, Monica V Estrada, Kimberly N Johnson, Yu Shyr, Harold L Moses, Melinda E Sanders, Jennifer A Pietenpol. PLoS One 2016
611
12

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
12

Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer.
Khaled Greish, Aanchal Mathur, Reem Al Zahrani, Sara Elkaissi, Muna Al Jishi, Osama Nazzal, Safa Taha, Valeria Pittalà, Sebastien Taurin. J Control Release 2018
24
16

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng,[...]. J Clin Oncol 2016
897
9


Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, Graham M Poage, Kyle R Covington, Alejandro Contreras, Suzanne A W Fuqua, Michelle I Savage, C Kent Osborne, Susan G Hilsenbeck, Jenny C Chang,[...]. Clin Cancer Res 2015
691
9

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Y Dirix, Istvan Takacs, Guy Jerusalem, Petros Nikolinakos, Hendrik-Tobias Arkenau, Andres Forero-Torres, Ralph Boccia, Marc E Lippman, Robert Somer, Martin Smakal,[...]. Breast Cancer Res Treat 2018
379
9

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
9


Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
Jenny G Parvani, Maneesh D Gujrati, Margaret A Mack, William P Schiemann, Zheng-Rong Lu. Cancer Res 2015
109
9

Triple-negative breast cancer and the potential for targeted therapy.
Jing-Ru Jhan, Eran R Andrechek. Pharmacogenomics 2017
120
9

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
9

Current approaches in treatment of triple-negative breast cancer.
Hanan Ahmed Wahba, Hend Ahmed El-Hadaad. Cancer Biol Med 2015
287
9

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
9

Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery.
Rajni Sinha, Gloria J Kim, Shuming Nie, Dong M Shin. Mol Cancer Ther 2006
388
9

Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance.
Gaofeng Xiong, Rachel L Stewart, Jie Chen, Tianyan Gao, Timothy L Scott, Luis M Samayoa, Kathleen O'Connor, Andrew N Lane, Ren Xu. Nat Commun 2018
106
9

Immune escape mechanisms as a guide for cancer immunotherapy.
Gregory L Beatty, Whitney L Gladney. Clin Cancer Res 2015
530
9

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
9

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, Suet-Feung Chin, Gulisa Turashvili, Oscar M Rueda, Mark J Dunning, Doug Speed, Andy G Lynch, Shamith Samarajiwa, Yinyin Yuan,[...]. Nature 2012
6

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
R Peto, C Davies, J Godwin, R Gray, H C Pan, M Clarke, D Cutter, S Darby, P McGale, C Taylor,[...]. Lancet 2012
6

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi, Mitsugu Yamamoto, Masako Sato, Ken-Ichi Watanabe, Katsushige Yamashiro, Masato Takahashi. Breast Cancer 2018
66
6

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
Leisha A Emens, Paolo A Ascierto, Phillip K Darcy, Sandra Demaria, Alexander M M Eggermont, William L Redmond, Barbara Seliger, Francesco M Marincola. Eur J Cancer 2017
303
6

The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Hitomi Mori, Makoto Kubo, Rin Yamaguchi, Reiki Nishimura, Tomofumi Osako, Nobuyuki Arima, Yasuhiro Okumura, Masayuki Okido, Mai Yamada, Masaya Kai,[...]. Oncotarget 2017
82
6

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
6

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
José Baselga, Patricia Gómez, Richard Greil, Sofia Braga, Miguel A Climent, Andrew M Wardley, Bella Kaufman, Salomon M Stemmer, António Pêgo, Arlene Chan,[...]. J Clin Oncol 2013
252
6

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, P-L Kellokumpu-Lehtinen, P Bono, V Kataja, C Desmedt,[...]. Ann Oncol 2014
810
6

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.
L Malorni, P B Shetty, C De Angelis, S Hilsenbeck, M F Rimawi, R Elledge, C K Osborne, S De Placido, G Arpino. Breast Cancer Res Treat 2012
120
6

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T Moore, Frances Collichio, David W Ollila, Carolyn I Sartor, Mark L Graham, Charles M Perou. Clin Cancer Res 2007
6

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Carsten Denkert, Cornelia Liedtke, Andrew Tutt, Gunter von Minckwitz. Lancet 2017
413
6

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. J Clin Oncol 2013
6


American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,[...]. J Clin Oncol 2010
6

Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2017
6

Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
Bruce G Haffty, Qifeng Yang, Michael Reiss, Thomas Kearney, Susan A Higgins, Joanne Weidhaas, Lyndsay Harris, Willam Hait, Deborah Toppmeyer. J Clin Oncol 2006
793
6

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
Fiona M Blows, Kristy E Driver, Marjanka K Schmidt, Annegien Broeks, Flora E van Leeuwen, Jelle Wesseling, Maggie C Cheang, Karen Gelmon, Torsten O Nielsen, Carl Blomqvist,[...]. PLoS Med 2010
623
6

Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY® System.
Ka-Wai Cheung, Qiaoli Peng, Liufen He, Kanru Cai, Qiang Jiang, Boping Zhou, Sabrina Wai-Chi To, Wing-Cheong Yam, Li Liu, Zhiwei Chen,[...]. PLoS One 2016
8
25

Triple negative breast cancer: the kiss of death.
Adriana-Andreea Jitariu, Anca Maria Cîmpean, Domenico Ribatti, Marius Raica. Oncotarget 2017
101
6

Triple-negative breast cancer: treatment challenges and solutions.
Joëlle Collignon, Laurence Lousberg, Hélène Schroeder, Guy Jerusalem. Breast Cancer (Dove Med Press) 2016
188
6

Triple-negative breast cancer: present challenges and new perspectives.
Franca Podo, Lutgarde M C Buydens, Hadassa Degani, Riet Hilhorst, Edda Klipp, Ingrid S Gribbestad, Sabine Van Huffel, Hanneke W M van Laarhoven, Jan Luts, Daniel Monleon,[...]. Mol Oncol 2010
209
6

Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
Anna Diana, Elisena Franzese, Sara Centonze, Francesca Carlino, Carminia Maria Della Corte, Jole Ventriglia, Angelica Petrillo, Ferdinando De Vita, Roberto Alfano, Fortunato Ciardiello,[...]. Curr Oncol Rep 2018
52
6

Nanocarriers as an emerging platform for cancer therapy.
Dan Peer, Jeffrey M Karp, Seungpyo Hong, Omid C Farokhzad, Rimona Margalit, Robert Langer. Nat Nanotechnol 2007
6

Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy.
Chandran Murugan, Kathirvel Rayappan, Ramar Thangam, Ramasamy Bhanumathi, Krishnamurthy Shanthi, Raju Vivek, Ramasamy Thirumurugan, Atanu Bhattacharyya, Srinivasan Sivasubramanian, Palani Gunasekaran,[...]. Sci Rep 2016
53
6

Tumor-Targeting Micelles Based on Linear-Dendritic PEG-PTX8 Conjugate for Triple Negative Breast Cancer Therapy.
Yujie Zhang, Yifei Lu, Yu Zhang, Xi He, Qinjun Chen, Lisha Liu, Xinli Chen, Chunhui Ruan, Tao Sun, Chen Jiang. Mol Pharm 2017
12
16

Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.
Behrad Darvishi, Leila Farahmand, Keivan Majidzadeh-A. Mol Ther Nucleic Acids 2017
26
7


Formulation and antitumorigenic activities of nanoencapsulated nifetepimine: A promising approach in treating triple negative breast carcinoma.
Aparajita Ghosh, Arijit Bhowmik, Suman Bhandary, Salil Putatunda, Aparna Laskar, Atanu Biswas, Sandip Dolui, Bhaswati Banerjee, Rajni Khan, Nirmalendu Das,[...]. Nanomedicine 2016
3
66

Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.
Abenaa M Brewster, Mariana Chavez-MacGregor, Powel Brown. Lancet Oncol 2014
142
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.